AVXL
Price
$9.22
Change
-$0.26 (-2.74%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
809.33M
43 days until earnings call
SAVA
Price
$1.81
Change
+$0.05 (+2.82%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
85.5M
30 days until earnings call
Interact to see
Advertisement

AVXL vs SAVA

Header iconAVXL vs SAVA Comparison
Open Charts AVXL vs SAVABanner chart's image
Anavex Life Sciences
Price$9.22
Change-$0.26 (-2.74%)
Volume$15.79K
Capitalization809.33M
Cassava Sciences
Price$1.81
Change+$0.05 (+2.82%)
Volume$4.59K
Capitalization85.5M
AVXL vs SAVA Comparison Chart in %
Loading...
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVXL vs. SAVA commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVXL is a Hold and SAVA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (AVXL: $9.48 vs. SAVA: $1.75)
Brand notoriety: AVXL and SAVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVXL: 318% vs. SAVA: 541%
Market capitalization -- AVXL: $809.33M vs. SAVA: $85.5M
AVXL [@Biotechnology] is valued at $809.33M. SAVA’s [@Biotechnology] market capitalization is $85.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVXL’s FA Score shows that 0 FA rating(s) are green whileSAVA’s FA Score has 1 green FA rating(s).

  • AVXL’s FA Score: 0 green, 5 red.
  • SAVA’s FA Score: 1 green, 4 red.
According to our system of comparison, both AVXL and SAVA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVXL’s TA Score shows that 6 TA indicator(s) are bullish while SAVA’s TA Score has 4 bullish TA indicator(s).

  • AVXL’s TA Score: 6 bullish, 3 bearish.
  • SAVA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AVXL is a better buy in the short-term than SAVA.

Price Growth

AVXL (@Biotechnology) experienced а +4.29% price change this week, while SAVA (@Biotechnology) price change was -12.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.84%, and the average quarterly price growth was +6.72%.

Reported Earning Dates

AVXL is expected to report earnings on Aug 12, 2025.

SAVA is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVXL($809M) has a higher market cap than SAVA($85.5M). AVXL YTD gains are higher at: -11.732 vs. SAVA (-25.847). AVXL has higher annual earnings (EBITDA): -45.65M vs. SAVA (-145.89M). SAVA (117M) and AVXL (116M) have equal amount of cash in the bank . SAVA has less debt than AVXL: SAVA (0) vs AVXL (88.2K). AVXL (0) and SAVA (0) have equivalent revenues.
AVXLSAVAAVXL / SAVA
Capitalization809M85.5M946%
EBITDA-45.65M-145.89M31%
Gain YTD-11.732-25.84745%
P/E RatioN/AN/A-
Revenue00-
Total Cash116M117M99%
Total Debt88.2K0-
FUNDAMENTALS RATINGS
AVXL vs SAVA: Fundamental Ratings
AVXL
SAVA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
21
Undervalued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
3965
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
49n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAVA's Valuation (21) in the Pharmaceuticals Other industry is somewhat better than the same rating for AVXL (60) in the Biotechnology industry. This means that SAVA’s stock grew somewhat faster than AVXL’s over the last 12 months.

AVXL's Profit vs Risk Rating (79) in the Biotechnology industry is in the same range as SAVA (100) in the Pharmaceuticals Other industry. This means that AVXL’s stock grew similarly to SAVA’s over the last 12 months.

AVXL's SMR Rating (96) in the Biotechnology industry is in the same range as SAVA (97) in the Pharmaceuticals Other industry. This means that AVXL’s stock grew similarly to SAVA’s over the last 12 months.

AVXL's Price Growth Rating (39) in the Biotechnology industry is in the same range as SAVA (65) in the Pharmaceuticals Other industry. This means that AVXL’s stock grew similarly to SAVA’s over the last 12 months.

AVXL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SAVA (100) in the Pharmaceuticals Other industry. This means that AVXL’s stock grew similarly to SAVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVXLSAVA
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
85%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 28 days ago
84%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HRIDX14.250.09
+0.64%
Harbor Diversified Intl All Cp Admin
PCUZX62.010.33
+0.54%
T. Rowe Price U.S. Equity Research Z
TQCCX18.950.06
+0.33%
Touchstone Dividend Equity C
HRVIX33.56N/A
N/A
Heartland Value Plus Investor
RSENX21.85-0.01
-0.05%
Victory Sophus Emerging Markets Y

AVXL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVXL has been loosely correlated with PLRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AVXL jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVXL
1D Price
Change %
AVXL100%
-0.94%
PLRX - AVXL
48%
Loosely correlated
-3.08%
TENX - AVXL
47%
Loosely correlated
-1.34%
AXON - AVXL
45%
Loosely correlated
+1.86%
RXRX - AVXL
44%
Loosely correlated
-6.85%
VCYT - AVXL
41%
Loosely correlated
+2.13%
More

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
-4.37%
CRSP - SAVA
35%
Loosely correlated
+1.69%
IBRX - SAVA
29%
Poorly correlated
-3.23%
LXRX - SAVA
26%
Poorly correlated
-11.66%
AMRN - SAVA
26%
Poorly correlated
-1.19%
VKTX - SAVA
26%
Poorly correlated
-5.86%
More